Insulet Co. (NASDAQ:PODD) Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd cut its stake in Insulet Co. (NASDAQ:PODD) by 75.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,272 shares of the medical instruments supplier’s stock after selling 12,943 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Insulet were worth $994,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PODD. Baillie Gifford & Co. boosted its holdings in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after purchasing an additional 389,639 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after acquiring an additional 75,526 shares during the last quarter. American Century Companies Inc. grew its position in Insulet by 18.7% during the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after acquiring an additional 139,246 shares during the period. Westfield Capital Management Co. LP increased its stake in Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after acquiring an additional 163,388 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Insulet by 43.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after acquiring an additional 193,839 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PODD. JPMorgan Chase & Co. boosted their target price on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday. Piper Sandler boosted their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Citigroup raised their target price on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday. Sanford C. Bernstein began coverage on shares of Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Finally, Barclays increased their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $267.44.

Insulet Trading Down 0.6 %

Shares of PODD opened at $271.73 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a one year low of $160.19 and a one year high of $279.77. The stock has a 50-day moving average price of $250.58 and a 200 day moving average price of $219.40. The company has a market capitalization of $19.06 billion, a P/E ratio of 46.53, a P/E/G ratio of 4.06 and a beta of 1.21.

Insider Activity

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.